KalVista Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

kalvista.com

Founded Year

2004

Stage

Reverse Merger | IPO

Total Raised

$45.8M

About KalVista Pharmaceuticals

KalVista Pharmaceuticals (NASDAQ: KALV) is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need. The company has developed a portfolio of small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

KalVista Pharmaceuticals Headquarter Location

55 Cambridge Parkway Suite 901E

Cambridge, Massachusetts, 02142,

United States

857-999-0075

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing KalVista Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

KalVista Pharmaceuticals is included in 2 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

B

Biopharma Tech

838 items

KalVista Pharmaceuticals Patents

KalVista Pharmaceuticals has filed 25 patents.

The 3 most popular patent topics include:

  • Coagulation system
  • EC 3.4.21
  • Diseases of the eye and adnexa
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/22/2019

2/8/2022

EC 3.4.21, Coagulation system, Rare diseases, Prodrugs, Pyridines

Grant

Application Date

1/22/2019

Grant Date

2/8/2022

Title

Related Topics

EC 3.4.21, Coagulation system, Rare diseases, Prodrugs, Pyridines

Status

Grant

Latest KalVista Pharmaceuticals News

KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference

Apr 11, 2022

April 11, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass. & SALISBURY, England--( BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:00 p.m. ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com . An audio archive will be available on KalVista’s website for 30 days following the presentations. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks and has initiated the Phase 3 KONFIDENT clinical trial. KVD824 is in development for prophylactic treatment of HAE, with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial. For more information about KalVista, please visit www.kalvista.com . Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT and Phase 2 KOMPLETE clinical trials, and to obtain regulatory approvals for KVD900, KVD824 and other candidates in development, the ability of KVD900, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Contacts

KalVista Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

KalVista Pharmaceuticals Rank

  • When was KalVista Pharmaceuticals founded?

    KalVista Pharmaceuticals was founded in 2004.

  • Where is KalVista Pharmaceuticals's headquarters?

    KalVista Pharmaceuticals's headquarters is located at 55 Cambridge Parkway, Cambridge.

  • What is KalVista Pharmaceuticals's latest funding round?

    KalVista Pharmaceuticals's latest funding round is Reverse Merger.

  • How much did KalVista Pharmaceuticals raise?

    KalVista Pharmaceuticals raised a total of $45.8M.

  • Who are the investors of KalVista Pharmaceuticals?

    Investors of KalVista Pharmaceuticals include Carbylan Therapeutics, SV Health Investors, Novo Holdings, Venrock, RA Capital Management and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.